Hepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major - impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy.

National Library of Canada - Thalassemia: Complications and Treatment



Description: -
-Hepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major - impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy.
-
n:o 21.
Tiedonantoja (Joensuun yliopisto. Yhteiskuntatieteiden tiedekunta) ; Occasional papers / University of Joensuu, Human Geography and Planning
n:o 21 =
Tiedonantoja / Joensuun yliopisto, Yhteiskuntatieteiden tiedekunta, Historiae naturalis classica -- 10
Canadian theses = -- Thèses canadiennesHepatic iron quantitation and liver biopsy in sickle cell disease and thalassemia major - impact on monitoring and preventing the progression of iron overload due to regular transfusion therapy.
Notes: Thesis (M.Sc.) -- University of Toronto, 2001.
This edition was published in 2001

Filesize: 47.106 MB

Tags: #Thalassemia: #Complications #and #Treatment

Iron

Given that, in adult patients with SCD, iron overload may result not only from prescribed, physician-monitored, chronic transfusion therapy, but also from the cumulative lifetime effects of potentially unindicated, episodic transfusions that patients receive in community hospitals perhaps unfamiliar with the treatment of SCD.

Design of Safe Nanotherapeutics for the Excretion of Excess Systemic Toxic Iron

This review focuses on the understanding of specific characteristics exploited by PLGA-based nanoparticles to target a specific organ or tissue or specific cells. In transfusional iron overload, transferrin is generally saturated so that NTBI plasma iron species are typically present at concentrations of 1-10μM. Prussian blue stain showing top figures hepatic iron in hepatocytes and portal macrophages, before left and after right 9 months of chelating therapy with the orally active chelating agent deferiprone in a patient with homozygous β thalassemia.

Non

We recommend treatment by phlebotomy of patients with non-HFE iron overload who have an elevated HIC. Usually, in untransfused patients, the reduction of hepatic iron is rapid, and if compliance is reasonable, deferoxamine therapy is rarely required for more than 18 months.

Sickle Hepatopathy

Furthermore, there are no available, reliable indicators of who will develop complications. The conjugation of DFO to a biodegradable scaffold dramatically increases its biocompatibility.

Physiology and pathophysiology of iron in hemoglobin

This article discusses these and other polymeric drugs in the setting of targeting to solid tumors.

Related Books

- Advertising identification and price guide
- Tax planning and corporate responsibilities of boardmembers - perspectives for companies in Germany,
- Magia ed esoterismo in Italia
- Residential adult education - a Canadian view.
- Basement - meditations on a human sacrifice